Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Timing of leucine supplements may boost muscle in seniors

NCT ID NCT06567665

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at when older men should take leucine supplements to best build muscle after exercise. Ten healthy men aged 65-75 will take leucine either with a meal or between meals after exercising. Researchers will measure how much new muscle protein is made to find the optimal timing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Leucine (a dietary supplement, an essential amino acid)
What this could lead to
If it works, this could point toward simple dietary strategies to help older adults maintain muscle mass and prevent frailty.
What could go wrong
This is a very small, early-stage study with only 10 healthy men aged 65-75. Results may not apply to women, less healthy people, or those who exercise regularly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 75 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male, 65-75 years of age * BMI 18-28 kg/m2 * Non smoker * Not performing regular resistance type exercise * Participant is willing and able to give informed consent for participation in the study Exclusion Criteria: * A BMI \<18 or \>28 kg·m-2 * Active cardiovascular disease: uncontrolled hypertension (BP \> 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event * Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial) * Respiratory disease including pulmonary hypertension or chronic obstructive pulmonary disease (COPD) * Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), inborn/ congenital errors of metabolism (e.g. phenylketonuria (PKU), galactosaemia) * Active inflammatory bowel disease * Acute infection * Acute or chronic renal disease * Malignancy (or history of malignancy with 5 y) * Recent steroid treatment (within 6 mo), or hormone replacement therapy * Coagulopathy * Musculoskeletal or neurological disorders * Known allergies to any of the product ingredients * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle protein synthesis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Nottingham

    RECRUITING

    Nottingham, Nottinghamshire, NG7 2UH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.